

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the Application. Claims 11, 20, 26 and 27 have been amended as follows: Underlines indicate insertions and ~~strikethroughs~~ indicate deletions.

Listing of Claims

Claims 1-10 (Cancelled)

11. **(Currently amended)** A method of detecting a level of an amino-terminally truncated CDP/Cux polypeptide ~~variant in a sample,~~ wherein said polypeptide is p75, and ~~wherein said method comprises polypeptide variant is:~~

- a) obtaining said sample;
- b) contacting said sample with an antibody which binds to said p75 polypeptide; and
- c) detecting said antibody bound to said p75 polypeptide.
- ~~a) a variant which is encoded by a nucleic acid produced from transcriptional initiation within intron 20 of the CDP/Cux locus;~~
- ~~b) a variant which is encoded by a CDP/Cux mRNA comprising a translation start site within exon 21;~~
- ~~e) a variant which lacks Cut repeat domains CR1 and CR2;~~
- ~~d) a variant which contains only two DNA binding domains; or~~
- ~~e) any combination of a) - d).~~

Claims 12-15 (Cancelled)

16. **(Previously presented)** The method of claim 11, wherein said sample is derived from breast tissue from a patient having or suspected of having breast cancer.

17. **(Previously presented)** The method of claim 11, wherein said sample is derived from blood from a patient having or suspected of having acute myeloid leukemia (AML).

18. **(Previously presented)** The method of claim 16, wherein detection of p75 in said breast tissue identifies said patient as having breast cancer.

19. **(Previously presented)** The method of claim 17, wherein detection of p75 in said blood identifies said patient as having acute myeloid leukemia (AML).

Claims 20-25 **(Cancelled)**

26. **(Currently amended)** A kit for detecting a level of an amino-terminally truncated CDP/Cux polypeptide variant in a sample, wherein said polypeptide variant is p75:

~~a) — a variant which is encoded by a nucleic acid produced from transcriptional initiation within intron 20 of the CDP/Cux locus;~~

~~b) — a variant which is encoded by a CDP/Cux mRNA comprising a translation start site within exon 21;~~

~~c) — a variant which lacks Cut repeat domains CR1 and CR2;~~

~~d) — a variant which contains only two DNA binding domains; or
any combination of a) - d); said kit comprising:~~

~~a) - a first vessel containing a reagent enabling the formation of an immune complex, wherein said immune complex comprises:~~

~~i) an antibody which recognizes said p75 polypeptide an amino-terminally truncated CDP/Cux polypeptide variant; and~~

- ii) ~~a n-amino terminally truncated CDP/Cux p75 polypeptide; variant that is:~~
 - ~~I) a variant which is encoded by a nucleic acid produced from transcriptional initiation within intron 20 of the CDP/Cux locus;~~
 - ~~II) a variant which is encoded by a CDP/Cux mRNA comprising a translation start site within exon 21;~~
 - ~~III) a variant which lacks Cut repeat domains CR1 and CR2;~~
 - ~~IV) a variant which contains only two DNA binding domains; or~~
 - ~~V) any combination of I) - IV); and~~
- b) –a second vessel containing a detecting reagent for identifying said immune complex.

27. **(Currently amended)** The kit of claim 26, wherein said detecting reagent is a second antibody conjugated to:

- a) an enzyme;
- b) a radioactive isotope;
- c) a fluorescent molecule;
- d) a chemiluminescent molecule; or
- e) a biotin molecule~~any combination of a) - d).~~

28. **(Previously presented)** The kit of claim 26, comprising guidelines for the detection of p75.